CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75 (male or female).
- Your lymphoma diagnosis is confirmed as DLBCL, and the tumor cells have CD19.
- Your lymphoma must have come back or not responded after at least two treatment lines, and you received rituximab plus an anthracycline.
- You must have at least one measurable spot the doctors can track (often seen on PET-CT).
- Your blood counts and organ functions (heart, liver, kidneys) must be good enough for treatment.
- You generally must not have certain recent treatments, infections, or other serious conditions (see questions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
This study tests a customized cancer treatment called CD19 CAR-T for people newly diagnosed with certain high-risk large B-cell lymphoma. It aims to see whether this treatment can help control the lymphoma, especially in higher-risk cases.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.